WO2022180265A2 - Methode de production d'une forme periplasmique de la proteine crm197 - Google Patents
Methode de production d'une forme periplasmique de la proteine crm197 Download PDFInfo
- Publication number
- WO2022180265A2 WO2022180265A2 PCT/EP2022/054914 EP2022054914W WO2022180265A2 WO 2022180265 A2 WO2022180265 A2 WO 2022180265A2 EP 2022054914 W EP2022054914 W EP 2022054914W WO 2022180265 A2 WO2022180265 A2 WO 2022180265A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- coli
- expression
- protein
- strain
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 37
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 title description 34
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 38
- 210000001322 periplasm Anatomy 0.000 claims abstract description 35
- 239000013604 expression vector Substances 0.000 claims abstract description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 4
- 230000014509 gene expression Effects 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 239000013612 plasmid Substances 0.000 claims description 44
- 235000018102 proteins Nutrition 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 230000006698 induction Effects 0.000 claims description 38
- 241000588724 Escherichia coli Species 0.000 claims description 31
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 9
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 9
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 7
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 6
- 230000001086 cytosolic effect Effects 0.000 claims description 6
- 230000002939 deleterious effect Effects 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 239000002028 Biomass Substances 0.000 claims description 4
- 108091035707 Consensus sequence Proteins 0.000 claims description 4
- 238000011210 chromatographic step Methods 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000007857 degradation product Substances 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 241000701867 Enterobacteria phage T7 Species 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000014621 translational initiation Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 230000008685 targeting Effects 0.000 abstract description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical group CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 16
- 230000012010 growth Effects 0.000 description 10
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 230000003204 osmotic effect Effects 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000699 Bacterial toxin Toxicity 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010060123 Conjugate Vaccines Proteins 0.000 description 4
- 102000016607 Diphtheria Toxin Human genes 0.000 description 4
- 108010053187 Diphtheria Toxin Proteins 0.000 description 4
- 108700028353 OmpC Proteins 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000000688 bacterial toxin Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229940031670 conjugate vaccine Drugs 0.000 description 4
- 239000000815 hypotonic solution Substances 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000819 hypertonic solution Substances 0.000 description 2
- 229940021223 hypertonic solution Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101150094313 XPO1 gene Proteins 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002333 glycines Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
- C12R2001/16—Corynebacterium diphtheriae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- the present invention relates to a method for producing a periplasmic form of the CRM197 protein, to the expression vector coding for the CRM197 protein and for the signal sequence, OmpC, allowing targeting of the CRM197 protein to the periplasmic space, as well as to the strain transformed by the expression vector.
- the recombinant protein CRM197, Cross Reacting Material, or CRM can be used for example as carrier protein in conjugate vaccines.
- a conjugate vaccine is a type of vaccine combining a weakly immunogenic antigen with a so-called "carrier" protein which has T epitopes recognized by the immune system, in order to obtain a stronger response to the antigen.
- CRM197 is a non-toxic mutant diphtheria toxin protein.
- hapten is one of the building blocks of an antigen which, when combined with a protein carrier, gives it sufficient antigenic potency to generate a humoral immune response.
- the CRM197 protein is a detoxified form of diphtheria toxin where a substitution of glycine at position 52 by a glutamic acid abolishes the ADP-ribosyltransferase activity of the native toxin and renders it non-toxic.
- the CRM197 protein comprises a single polypeptide chain of 535 amino acids, with a molecular weight of 58.4 kDa.
- the CRM197 gene was originally cloned in Corynebacterium diphtheriae, the pathogenic bacterium causing diphtheria and containing the native toxin. Like the native toxin, CRM197 is only very weakly secreted. Consequently, considerable efforts have been made to produce the CRM197 protein in other bacteria.
- the CRM197 protein is used as a carrier protein in several conjugate vaccines. For example, Hibtiter TM , a vaccine to protect against Haemophius influenzae type b, approved by the FDA 'Food and Drug Administration' in 1990 was the first conjugate vaccine to use the CRM197 protein as carrier protein; the hapten is a sugar.
- the CRM197 protein also has a binding site for HB-EGF 'heparin-binding epidermal growth factor-like growth factor', a member of the EGF family. As this EGF receptor is overexpressed in many cancer cells, the literature indicates that the CRM197 protein could also be used as a potential agent in targeted anti-cancer therapies. The demand for having an industrial production of the CRM197 protein is therefore growing. Unfortunately, at the production level of CRM197, it is always difficult to achieve high and stable expression levels of the CRM197 protein in the native strain. Wild-type E. coli BL21 bacteria. An insoluble form of the CMR197 protein can be produced at a relatively high level by fermentation in E.
- the production of the CRM197 protein in an E. coli strain K12 is known from document EP3113800.
- This document relates to a method for producing a recombinant CRM197 protein in a host cell of E. coli.
- the method comprises incubating an E. coli strain having a reduced genome comprising an expression vector comprising a nucleic acid sequence encoding the protein CRM197 operably linked to a sequence of expression control under conditions suitable for the expression of the recombinant CRM197 protein.
- a significant increase in the yield of CRM197 is obtained in a host cell of E.
- EP3170837 provides an improved method of producing a bacterial toxin by periplasmic expression comprising the steps of a) growing a culture of the bacterial host cell containing an expression vector in which particular signal peptide sequences are linked to the sequence of a bacterial toxin and b) inducing expression of the polypeptide containing particular signal peptide sequences bound to a bacterial toxin such that a bacterial toxin is expressed and secreted into the periplasm.
- EP2445930 proposes a process for the production of the CRM197 protein and similar proteins, as an alternative to the use of the microorganism Corynebacterium diphtheriae. According to the procedure described in this document, the protein of interest can be obtained in large quantities both for basic research and for applications in the medical-therapeutic field.
- EP3444269 describes an expression system for producing a diphtheria toxin polypeptide in a strain of E. coli deficient for rhamnose catabolism. This document describes an expression system comprising a rhamnose-inducible promoter sequence and an expression sequence comprising a first portion with a signal sequence and a second portion comprising the diphtheria toxin sequence.
- the present invention provides an expression system allowing a high and stable expression yield over time and which has optimized ratios between the rate of synthesis and that of secretion of the CRM197 protein (SEQ ID NO:12) as well as a purification yield allowing commercial exploitation and provision of SEQ ID NO:12 as a protein/peptide for the subsequent development of vaccines or targeted therapies.
- SEQ ID NO:12 the CRM197 protein
- the inventors sought to produce SEQ ID NO: 12 in yeast, which is advantageous for the downstream purification steps; unfortunately it didn't work.
- the inventors used plasmids with a very high copy level or with an optimal promoter, so as to allow massive synthesis of SEQ ID NO: 12 in E. coli or in its periplasmic space.
- the present invention provides a Gram-negative prokaryotic expression vector having the following characteristics: (i) a low copy number origin of replication, the low copy number being defined by a plasmid copy number of 20 per cell or less, (ii) a promoter sequence inducible to an exogenous inducing agent, (iii) a medium strength ribosome binding site, the medium strength ribosome binding site corresponds to a sequence in mRNA modified to have reduced ribosome binding, (iv) a protein coding sequence having at least 95% identity to complete SEQ ID NO:12.
- the inducible promoter sequence has an identity of at least 95% with respect to SEQ ID NO: 5 over the entire length and is recognized specifically by an RNA polymerase of phage T7.
- the medium strength ribosome binding site is defined by a consensus sequence SEQ ID NO:6 or by the consensus sequence SEQ ID NO:6 comprising an addition and/or a deletion and/or a point mutation of 1 or 2 or 3 or 4 or 5 nucleotides, SEQ ID NO: 6 being located upstream of a translation initiation site.
- the present invention also relates to a transformed strain of E. coli bacteria comprising the expression vector.
- the E. coli BL21 T7XB strain was deposited in the name of Xpress Biologicals at the BCCM 'Belgian Co-ordinated Collections of Microorganisms' in Ghent on 23/12/2020 under the reference LMBP 12507.
- a strain of E. coli BL21 bacteria defined by a deletion of the ⁇ DE3 prophage with the exception of the genes necessary for expression of the RNA polymerase of the T7 phage: E. coli BL21( ⁇ DE3) or E.
- the present invention also relates to a method for producing in the periplasmic space a peptide having an identity of at least 95% with respect to SEQ ID NO: 12 over its entire length comprising: (i) a transformation of a strain of E. coli by a vector allowing the expression of SEQ ID NO: 12 in the periplasmic space of the transformed E. coli strain, the expression being inducible by an exogenous agent, (ii) a culture of the transformed E. coli strain at a substantially constant temperature, for example 37° C.
- the substantially constant temperature is a temperature compatible with optimal growth metabolism of the transformed E. coli strain.
- the E. coli strain is the BL21 strain defined by a deletion of the ⁇ DE3 prophage with the exception of the genes necessary for expression of the RNA polymerase of the T7 phage.
- the production in the periplasmic space of a peptide having an identity of at least 95% with respect to SEQ ID NO: 12 over its entire length is ensured by an addressing signal peptide in the periplasmic space, the signal peptide having a sequence identity to SEQ ID NO:2 of at least 95%.
- the reduced temperature is 23° C. ⁇ 0.5° C.
- the predetermined duration of the induction phase is between 15 and 25 h, preferably between 6 and 10 p.m. and more particularly around 8 p.m. and/or the pH of the induction phase is between 6.8 and 7.5, preferably between 7.0 and 7.2.
- the expression inducible by an exogenous agent is carried out by an on/off induction system and where the exogenous agent is isopropyl- ⁇ -D-1-thiogalactopyranoside. Isopropyl- ⁇ -D-1-thiogalactopyranoside is also known as IPTG.
- the culture and the induction phase are devoid of antibiotics such as, for example, kanamycin, ampicillin, streptomycin, chloramphenicol, or tetracycline.
- antibiotics such as, for example, kanamycin, ampicillin, streptomycin, chloramphenicol, or tetracycline.
- the expression vector is low copy number defined by a plasmid copy number of 20 per cell or less and/or the ribosome binding sequence is of medium strength.
- the purification of the protein SEQ ID NO:12 comprises the successive steps of: (i) clarification of the supernatant resulting from the periplasmic extraction containing the components of the periplasmic space and the protein SEQ ID NO:12 by at least a filtration step, preferably two filtration steps with recovery of a filtrate comprising SEQ ID NO: 12, optionally, (ii) a series of chromatographic steps arranged to recover SEQ ID NO:12 in a fraction to be kept and the contaminants in one or more fractions to be eliminated, (iii) optionally, an elimination of residual endotoxins, and (iv) optionally , a sterilization of the fraction comprising SEQ ID NO: 12 to be preserved, devoid of endotoxins.
- the periplasmic extraction is a periplasmic extraction by osmotic shock.
- the periplasmic extraction comprises the steps of: (i) suspending the pellet formed by the bacteria collected in a hypertonic solution to form a hypertonic suspension of bacteria, (ii) transferring the hypertonic suspension of bacteria into a second mixing vessel through a diffusion ring and by means of a transfer tubing and a first pump, (iii) feeding said mixing vessel with a hypotonic solution by means of a transfer tubing and a second pump, so as to cause an osmotic shock on the bacteria of the hypertonic suspension in the second mixing container, the osmotic shock allowing the release of the contents of the periplasmic space into the solution of the second mixing container, (iv) drawing off the mixture so that the residence time of the bacteria in the suspension of bacteria in the second container is between 10 seconds and one minute, more preferably around 30 seconds and that the volume of the mixture in the second container is kept constant, the withdrawal being carried out
- the series of chromatographic steps comprises a first chromatography on anion exchange resin and a second chromatography on a hydrophobic resin.
- the present invention finally relates to a method for selecting a signal peptide so as to optimize production of a protein of interest in the periplasmic space of the bacterium E. coli in which: - a genetic construct is generated comprising a rhamnose-inducible promoter having a sequence identity of at least 95% with respect to SEQ ID NO: 7 controlling the expression of the protein of interest arranged with the signal peptide to be tested, - the bacterium E. coli with the genetic construction, - several parallel cultures of the transformed E.
- coli bacterium are carried out in a culture medium devoid of rhamnose, - the transformed E. coli bacterium is cultivated in the presence of a determined concentration of rhamnose so as to obtain a weak induction of the expression of the protein of interest and another culture of the bacterium E.
- the deleterious effects on metabolism are quantified, for example, by establishing a score associated with the signal peptide and protein couple of interest where several deleterious effects are taken into account such as the loss of the plasmid, the reduction in the bacterial biomass, the formation of cytosolic aggregates or degradation products and partial cleavage of the signal peptide.
- the signal peptide associated with this protein of interest is cleaved during transport to the periplasmic space. A partial cleavage of the signal peptide can therefore generate an undesired modification of the functionality of the protein of interest.
- FIG. 1 shows the different stages of production by fermentation of the protein SEQ ID NO: 12.
- FIG. 2 presents the different stages of purification of the protein SEQ ID NO:12.
- FIG. 3 shows an expression of the protein SEQ ID NO:12 using an optical density measurement at 600 nm of the cultures of E. coli BL21 (DE3) inoculated with different expression vectors.
- Plasmid pD431 low plasmid copy number
- plasmid pD451 high plasmid copy number.
- MR medium ribosome binding strength
- SR high ribosome binding strength.
- the strain of E. coli BL21 T7XB transformed with an expression vector pLM7-OC-CRM (step I of figure 1) is cultured at a constant temperature of 37° C. ⁇ 0.5° C. and a constant pH of 7.0 ⁇ 0 ,2. More particularly, the culture (stage II to IV of FIG. 1) of the E. coli strain BL21 T7XB transformed by the expression vector pLM7-OC-CRM at a constant temperature of 37° C.
- stage V of figure 1 a preculture under agitation in a flask (stage II of figure 1), (ii) a growth in 'batch' mode in a bioreactor (stages III and IV of figure 1), (iii) a growth in 'fed-batch' mode in the bioreactor (stages III and IV in Figure 1).
- the bioreactor is for example a 50L bioreactor, fed through a 0.2 ⁇ m sterilizing filter with 35L of GYPSCI medium, glycerol and yeast extract.
- the cell pellet formed from the separated bacteria is then stored at low temperature; ex -20°C or even less (step VII of Figure 2).
- the bacteria collected are then used as basic material for carrying out a periplasmic extraction (steps VIII and IX of FIG. 2 and see example 4).
- a purification of the latter is carried out as described above (steps X to XIV of FIG. 2). More particularly, the series of chromatographic steps comprises a first chromatography on anion exchange resin (step XI of FIG. 2) and a second chromatography on a hydrophobic resin (step XII of FIG. 2).
- the next filtration step is an ultrafiltration step (step XIV of FIG. 2).
- the first step of the ultrafiltration process consists in concentrating SEQ ID NO: 12 to approximately 4.5 mg/mL and the second step in diafiltering the concentration retentate against a 10 times larger volume of formulation buffer (phosphate buffer 15 mM, 5% sucrose, pH 7.35).
- formulation buffer phosphate buffer 15 mM, 5% sucrose, pH 7.35.
- the 30 kDa hollow fiber was selected because it corresponds to that having the highest cut-off threshold capable of retaining SEQ ID NO: 12.
- an additional step of elimination of residual endotoxins can be carried out (step XIII of FIG. 2), more particularly on a membrane containing in its coating groups of quaternary ammonium.
- Example 1 Preparation of the expression vector
- E. coli To select the vector allowing periplasmic expression by E. coli, several signal peptides were fused to the N-terminal part of SEQ ID NO: 12 within an inducible vector to rhamnose. After transformation of E. coli BL21 (DE3) by these different combinations, the expression of SEQ ID NO: 12 in each clone was evaluated by immunoblot analysis for different rhamnose concentrations, and therefore for different levels of induction .
- a selection matrix was constituted in order to select the signal peptide-SEQ ID NO:12 combinations which will then be tested for their expression after induction with IPTG.
- Table 1 shows the attribution of the scores as well as the cumulative scores, calculated by multiplying the scores obtained for the three criteria and for the three levels of induction. The highest cumulative score represents the construct expressing the greatest quantity of periplasmic SEQ ID NO:12, in the absence of cytoplasmic SEQ ID NO:12, without degradation or aggregation. If the score of the TorT-SEQ ID NO:12 construct is significantly higher than for the other variants, except at 11 mM, the cleavage of the signal peptide during secretion leaves an additional alanine residue at the beginning of the N- end.
- SEQ ID NO: 12 The identity of the SEQ ID NO: 12 produced is not 100%, which led the inventors to discard this variant.
- Two candidates were selected for screening for vectors inducible to IPTG: SEQ ID NO:9 – SEQ ID NO:12 (OmpA-CRM197) and SEQ ID NO:2 – SEQ ID NO:12 (OmpC-CRM197).
- Table 1 Matrix used to select signal peptide-SEQ ID NO:12 (CRM197) combinations
- Figure 3 shows, for eight different expression systems in terms of plasmid copy number ( ⁇ 20 and ⁇ 500 copies), ribosome binding strength (average binding following a modification of the mRNA sequence and binding forte) as well as the signal peptide SEQ ID NO: 2 (OmpC) and SEQ ID NO: 9 (OmpA), that the OD600 of the cultures induced for 4 h with IPTG are much lower than those non-induced or auto- lactose-induced.
- the optical density at 600 nm of the culture medium in the flask, OD600 is measured by spectrophotometry according to a standard protocol well known to those skilled in the art for measuring the optical density and taking into account a blank measurement corresponding to the optical density of culture medium without bacteria.
- the inventors conclude from this that the SEQ ID NO: 12 produced too quickly and too much is toxic and/or that its synthesis represents a substantial metabolic load for the bacterium, thereby slowing down bacterial growth.
- This result demonstrates the importance of dissociating the biomass production and expression phases of SEQ ID NO: 12 and of inducing expression in a sufficiently slow and controlled manner, in order to avoid any phenomenon of toxicity, overload metabolic and/or saturation of the secretory pathways.
- coli BL21(DE3) were selected for the final selection carried out in a 5L bioreactor, a bioreactor representative of the conditions used for production on an industrial scale: BL21(DE3)/pD431-MR-OmpC-CRM197 (also called BL21(DE3) / pLM7-OC-CRM) which has a nucleotide sequence SEQ ID NO: 10 and BL21(DE3)/pD451-SR-OmpC-CRM197 (also called BL21(DE3)/pHS7-OC-CRM) which has a nucleotide sequence SEQ ID NO: 11.
- the first system of expression comprises elements ensuring slow expression of SEQ ID NO: 12 (low number of plasmid copies, medium binding to the ribosome) avoiding any phenomenon of toxicity, metabolic overload and/or saturation of the secretory pathways while the second includes elements in favor of a rapid expression of the protein (high number of copies of plasmid, strong binding to the ribosome).
- the second vector was nevertheless selected in anticipation of low plasmid stability.
- the expression levels of the two expression systems (BL21(DE3)/pLM7-OC-CRM and BL21(DE3)/pHS7-OC-CRM) were compared under conditions representative of industrial conditions.
- a condition which combines the expression of the highest SEQ ID NO: 12 and high plasmid stability involves low plasmid copy number, medium ribosome attachment, and temperature upon induction of 23° C., which corresponds to a set of factors allowing slow and controlled expression of SEQ ID NO: 12.
- condition F03 The conditions leading to the weakest expression (condition F03) or to the weakest plasmid stability (condition F06) involve a high plasmid copy number and strong ribosome binding, a factor leading to rapid expression of SEQ ID NO:12 and responsible for phenomena of toxicity, metabolic overload and/or saturation of the secretory pathways.
- Table 2 Expression levels and plasmid stabilities in 5L reactor - Strain E. colt BL21 (DE3)
- Example 2 Preparation of the bacterial strain containing the expression vector
- Three bacterial strains were transformed with different vectors containing SEQ ID NO:12 fused to the signal peptide SEQ ID NO:2 (OmpC): ⁇ E. coli BL21, a strain characterized by the absence of the ⁇ DE3 prophage and by the use bacterial polymerase T5 whose transcription efficiency does not reach that of prophage T7 polymerase;
- E. coli BL21 ⁇ DE3 or E. coli BL21 T7XB, a proprietary strain characterized by the deletion of the prophage sequence, with the exception of the genes necessary for the expression of the T7 polymerase.
- Table 3 compares the different expression systems involving the three strains tested (E. coli BL21, E. coli BL21 (DE3) and E. coli BL21 T7XB) in terms of plasmid copy number, type of promoter (T5 or T7) and ribosome binding strength (medium and strong) as well as the results obtained during the microplate cultures (OD 600 and cytoplasmic expression level of SEQ ID NO: 12).
- E. coli BL21 ⁇ DE3
- E. coli BL21 T7XB a proprietary strain characterized by the deletion of the prophage sequence, with the exception of the genes necessary for the expression of the T7 polymerase.
- Table 3 compares the different expression systems involving the three strains tested (E. coli BL21
- coli BL21 bacteria characterized by a lower efficiency of bacterial polymerase T5, bacterial growths (OD 600 ) are not significantly (or little) impacted during induction with IPTG whereas that the expression levels evaluated by immunoblot analysis are low with the exception of that obtained for the strain transformed by a vector involving a high copy number and a strong binding to the ribosome.
- An absence of toxicity on bacterial growth and a significant expression are observed during induction with IPTG for the E coli BL21 (DE3) strain transformed by a plasmid involving a low number of copies and an average binding to the ribosome; all other constructs being subject to toxicity and/or low expression.
- the results obtained for the E. coli BL21 T7XB strain are similar to those obtained for the E. coli BL21 (DE3) strain.
- the expression levels as well as the plasmid stabilities were determined for the three bacterial strains (E. coli BL21, E. coli BL21 (DE3) and E. coli BL21 T7XB transformed with different vectors containing SEQ ID NO: 12 fused to the signal peptide SEQ ID NO: 2 under conditions representative of industrial conditions
- the cultures were carried out in 5 L fermenters which are designed, used and controlled in an identical manner to industrial production fermenters, in particular in terms of the agitation and aeration cascade.
- the cultures reach high cell densities through the adoption of “fed-batch” type feeding strategies.
- Expression levels, plasmid stabilities recorded for the different constructs and the conditions tested are summarized in Table 4.
- the four constructions involving the strain E coli BL21 characterized by the lower efficiency of the bacterial polymerase T5 presents levels of express high ions between 1.02 and 2.46 g/L and high plasmid stability (between 97 and 100%), whatever the number of plasmid copies and the ribosome binding strength.
- E coli BL21 (DE3) strain only constructs involving a low plasmid copy number and medium ribosome binding exhibit high expression levels between 1.00 and 3.10 g/L and plasmid stability. high (between 94 and 100%).
- coli BL21 (T7XB) strain characterized by the deletion of the prophage sequence, with the exception of the genes necessary for the expression of polymerase 17, a high level of expression (1.62 g/L) and high plasmid stability (97%) are recorded for the construction involving low plasmid copy number and medium ribosome binding while low expression level (0.62 g/L) and low plasmid stability ( 23%) are observed with the strain transformed by a vector implying a low plasmid copy number and a strong binding to the ribosome.
- Table 4 Expression levels and plasmid stabilities in a 5L reactor: E. coli BL21, E. coli BL21 (DE3) and E. coli BL21 T7XB strains
- E. coli BL21 T7XB strain characterized by the deletion of the prophage sequence, with the exception of the genes necessary for the expression of the T7 polymerase, was retained for the production of SEQ ID NO: 12.
- the inventors have determined that controlling expression in the presence of an expression system based on bacterial T5 RNA polymerase (E coli BL21), sometimes leads to leakage phenomena and less robustness. and, on the other hand, that the presence of the ⁇ DE3 prophage in the E. coli BL21 (DE3) strain presents a potential reactivation of the lytic cycle and therefore a non-negligible industrial risk.
- telomere length is a parameter that influences the expression of the CRM197 protein.
- telomere length is a parameter that influences the expression of the CRM197 protein.
- Too high an expression level can generate strong cytoplasmic production of the CRM1 97 protein, in insoluble form, reduce cell viability, without generating significant periplasmic production.
- Step 1 Preculture in flask Flask volume: 500 ml to 2 L, inoculation OD 600 : 0.005, culture medium: YGP, kanamycin: 25 mg/L, temperature: 37°C, agitation: 270 rpm, culture duration: 7h +/- 1 h.
- step 4 induction phase
- step 4 induction phase
- the temperature applied during the induction is a parameter that has a weak impact on the level of expression but not on the plasmid stability (comparison of the conditions FO1 and F02).
- the pH is a parameter that significantly impacts the level of expression and, to a lesser extent, the plasmid stability; a pH of 6.5 being less favorable while a pH of 7.0 is optimal for these two criteria.
- the absence of kanamycin, a decrease in temperature from 28 to 23°C during induction and a pH of 7.0 kept constant throughout the culture stages allow a good production yield of SEQ ID NO: 12.
- Table 5 Expression levels and plasmid stabilities in a 51 reactor: impact of kanamycin, temperature and pH
- the E. coli BL21 T7XB bacteria transformed with the vector pLM7-OC-CRM (SEQ ID NO: 10) are centrifuged and the cell pastes are frozen at -20°C.
- the periplasmic extraction starts by thawing the 1350 g cell pastes for 15h +/- 5h at 6°C +/- 2°C.
- Cell pastes are diluted 2:1 (v/w) in a hypertonic solution (50 mM Tris, 5 mM EDTA, 20% Sucrose, pH 8.0), mixed for 15 min and pumped with 'a first pump in a mixer through a diffusion ring whose flow is 121 ml/min.
- An osmotic shock of the cell suspension is then carried out thanks to a dilution of the cell suspension contained in the mixer using a hypotonic solution (MgCl 2 5 mM) which is pumped with a second pump in the mixer containing the suspension cell with a flow of 279 ml/min and a dilution ratio of 2.3:1 (v/v) of hypotonic solution.
- the temperature of the hypotonic solution is between 4 and 8°C.
- the volume of the cell suspension in the mixer is 200 ml and the residence time of the cell suspension in the mixer is 30 sec.
- a third pump ensures the extraction of the cell suspension from the mixer, which is collected in centrifuge pots, at a flow rate of 400 ml/min so as to maintain a constant cell suspension volume of 200 ml in the mixer.
- a 1350g weight of cell paste yields approximately 13.4 liters of osmotic shocked cell suspension.
- Example 5 Clarification of the supernatant containing the components of the periplasmic space and SEQ ID NO: 12
- the clarification of the supernatant resulting from the centrifugation of the cell suspension after osmotic shock (see example 4) consists of two serial filtration steps .
- the supernatant is pumped with a flow rate of 400 ml/min through a filter whose mesh size is 0.8-0.45 ⁇ m and whose area is 0.2 m 2 .
- the solution filtered for the first time is then pumped with a flow rate of 400 ml/min through a second filter whose mesh size is 0.45 - 0.22 ⁇ m and whose area is 0.1 m 2 , which makes it possible to obtain a solution containing a clarified periplasmic extract.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023552214A JP2024507994A (ja) | 2021-02-26 | 2022-02-28 | タンパク質crm197のペリプラズム形態を産生する方法 |
CN202280017425.6A CN116964206A (zh) | 2021-02-26 | 2022-02-28 | 生产蛋白crm197的周质形式的方法 |
EP22710025.2A EP4298224A2 (fr) | 2021-02-26 | 2022-02-28 | Methode de production d'une forme periplasmique de la proteine crm197 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE20215137A BE1029145B1 (fr) | 2021-02-26 | 2021-02-26 | Methode de production d'une forme periplasmique de la proteine crm197 |
BEBE2021/5137 | 2021-02-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022180265A2 true WO2022180265A2 (fr) | 2022-09-01 |
WO2022180265A3 WO2022180265A3 (fr) | 2022-10-20 |
Family
ID=74853484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/054914 WO2022180265A2 (fr) | 2021-02-26 | 2022-02-28 | Methode de production d'une forme periplasmique de la proteine crm197 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4298224A2 (fr) |
JP (1) | JP2024507994A (fr) |
CN (1) | CN116964206A (fr) |
BE (1) | BE1029145B1 (fr) |
WO (1) | WO2022180265A2 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011126811A2 (fr) | 2010-03-30 | 2011-10-13 | Pfenex Inc. | Expression de protéines de toxines recombinantes en forte quantité |
EP2445930A1 (fr) | 2009-06-25 | 2012-05-02 | Consorzio Interuniversitario per lo Sviluppo dei Sistemi a Grande Interfase, C.S.G.I | Expression bactérienne d'un gène artificiel pour produire crm197 et ses dérivés |
EP3113800A1 (fr) | 2014-03-03 | 2017-01-11 | Scarab Genomics, LLC | Production accrue de crm197 recombinante chez e. coli |
EP3170837A2 (fr) | 2009-10-08 | 2017-05-24 | GlaxoSmithKline Biologicals S.A. | Système d'expression |
EP3444269A1 (fr) | 2017-08-17 | 2019-02-20 | National Research Council of Canada | Systèmes et méthodes pour la production de polypeptides de toxine diphterique |
-
2021
- 2021-02-26 BE BE20215137A patent/BE1029145B1/fr active IP Right Grant
-
2022
- 2022-02-28 WO PCT/EP2022/054914 patent/WO2022180265A2/fr active Application Filing
- 2022-02-28 JP JP2023552214A patent/JP2024507994A/ja active Pending
- 2022-02-28 CN CN202280017425.6A patent/CN116964206A/zh active Pending
- 2022-02-28 EP EP22710025.2A patent/EP4298224A2/fr active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2445930A1 (fr) | 2009-06-25 | 2012-05-02 | Consorzio Interuniversitario per lo Sviluppo dei Sistemi a Grande Interfase, C.S.G.I | Expression bactérienne d'un gène artificiel pour produire crm197 et ses dérivés |
EP3170837A2 (fr) | 2009-10-08 | 2017-05-24 | GlaxoSmithKline Biologicals S.A. | Système d'expression |
WO2011126811A2 (fr) | 2010-03-30 | 2011-10-13 | Pfenex Inc. | Expression de protéines de toxines recombinantes en forte quantité |
EP3113800A1 (fr) | 2014-03-03 | 2017-01-11 | Scarab Genomics, LLC | Production accrue de crm197 recombinante chez e. coli |
EP3444269A1 (fr) | 2017-08-17 | 2019-02-20 | National Research Council of Canada | Systèmes et méthodes pour la production de polypeptides de toxine diphterique |
Non-Patent Citations (1)
Title |
---|
PHILIPPE GOFFIN, BIOTECHNOL. J., vol. 12, 2017, pages 1700168 |
Also Published As
Publication number | Publication date |
---|---|
EP4298224A2 (fr) | 2024-01-03 |
JP2024507994A (ja) | 2024-02-21 |
BE1029145B1 (fr) | 2022-09-27 |
BE1029145A1 (fr) | 2022-09-19 |
WO2022180265A3 (fr) | 2022-10-20 |
CN116964206A (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3976685B2 (ja) | タンパク質分泌のためのClyA溶血素の使用 | |
CN107058370A (zh) | 蛋白质表达或阻抑的系统、方法和设备 | |
FR2920158A1 (fr) | Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques | |
CN113502254B (zh) | 橄榄醇合成酶变体和表达其的工程化微生物 | |
FR2500847A1 (fr) | Marqueurs genetiques selectifs pour cellules eucaryotes, procede de mise en oeuvre de tels marqueurs et application des cellules contenant un tel marqueur a la fabrication de proteines determinees apres leur transformation par un adn correspondant | |
WO2022180265A2 (fr) | Methode de production d'une forme periplasmique de la proteine crm197 | |
CN113502255A (zh) | 用于生产橄榄醇和橄榄醇酸的工程化微生物 | |
EP0725140B1 (fr) | Procédé d'extraction de protéines périplasmiques de microorganismes procaryotes en présence d'arginine | |
US11639515B2 (en) | Genetically engineered strain for producing porcine myoglobin and food-grade fermentation and purification thereof | |
FR2780416A1 (fr) | Procede industriel de production de proteines heterologues chez e. coli et souches utiles pour le procede | |
CN113025599B (zh) | 一种重组溶组织梭菌i型胶原酶及其制备方法和应用 | |
WO2007099231A1 (fr) | Systeme d'expression d'un gene d'interet chez la levure | |
CA3159388A1 (fr) | Souche de champignon ayant une viscosite diminuee | |
WO2000024922A1 (fr) | Procede de production in vivo de proteines chimiquement diversifiees par incorporation d'acides amines non conventionnels | |
EP0771872A1 (fr) | Procédé de polymèrisation de séquences d'acides nucléiques et ses applications | |
KR101912631B1 (ko) | 막 단백질 제조용 융합 단백질, 발현 벡터, 및 이를 이용한 막 단백질 제조방법 | |
CN111733123B (zh) | 一种大规模发酵铁蛋白的方法 | |
EP3601545B1 (fr) | Production d'arn par des levures a particules pseudo-virales recombinantes | |
CN109553667B (zh) | 烟草kup2基因及应用 | |
FR2787121A1 (fr) | Nouvelle methode d'isolement et de selection de genes codant pour des enzymes, et milieu de culture approprie | |
EP1692291A2 (fr) | Systeme d'expression inductible de proteines recombinantes chez les cyanobacteries | |
JP2002345464A (ja) | 非選択圧下に高いコピー数を維持できる2ミクロン型ベクター | |
CN115873833A (zh) | 生产免疫球蛋白g降解酶的工程菌株和工艺 | |
EP1280890A1 (fr) | Souches mutantes capables de produire des proteines chimiquement diversifiees par incorporation d'acides amines non conventionnels | |
US20110124088A1 (en) | Expression vector for expressing recombinant protein in Cyanobacterium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22710025 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280017425.6 Country of ref document: CN Ref document number: 2023552214 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023016671 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023016671 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230818 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022710025 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022710025 Country of ref document: EP Effective date: 20230926 |